CORONA Remedies Acquires Wokadine® from Dr. Reddy's
Ahmedabad, March 30, 2026 – CORONA Remedies Limited (BSE: 544644, NSE: CORONA) announced today the acquisition of Wokadine® from Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY). This acquisition, effective March 30, 2026, marks CORONA Remedies’ fifth acquisition.The acquisition of Wokadine®, a brand ranked #2 in the Povidone Iodine India market, reinforces CORONA’s commitment to healthcare and enables deeper penetration into specialty markets. The brand holds potential for accelerated growth under CORONA Remedies’ management.
CORONA Remedies will leverage Wokadine®’s legacy of 46 years of trust and protection, increasing equity among Surgeons, ENT, General Physicians & Gynaecologists. The acquisition integrates Wokadine® into CORONA Remedies’ portfolio, marking its entry into the INR 648 Cr Povidone Iodine market.
The company’s sales & marketing team and distribution network will distribute the newly acquired portfolio across India. Wokadine® comprises 14 SKUs with various applications. The acquisition will be funded through internal accruals and cash.
According to Mr. Tejas Kothari, Vice President - Corporate Strategy & Business Development: "This acquisition will enhance and strengthen our existing product portfolio. By building on our strong relationships with healthcare professionals, we aim to deepen market penetration and are confident in accelerating the growth of this brand."
CORONA Remedies Limited, founded in 2004, develops, manufactures & markets branded pharmaceutical formulations in therapeutic areas including women’s healthcare, cardio-diabetes, pain management, and urology. The company operates WHO-GMP/EU GMP-certified manufacturing plants and has two DSIR-approved R&D centers with over 100 scientists. CORONA Remedies employs more than 5000 people.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.